Company
ATXA Therapeutics
- Biotech
- Founded:
- 2015
- Location:
- Dublin, Ireland
Description
ATXA Therapeutics develops selective small-molecule thromboxane receptor (TP) antagonists, including lead candidate NTP42, to treat cardiopulmonary diseases and pulmonary arterial hypertension for clinicians and patients.
ATXA Therapeutics is located in the Dublin ecosystem.
Related
Breye TherapeuticsBreye Therapeutics develops orally administered ophthalmology drugs, including danegaptide and P2X7 receptor antagonists, to treat retinal…
Confo TherapeuticsConfo Therapeutics develops GPCR-directed small-molecule and antibody therapies with proprietary technology that targets class A and B…
NeuromodNeuromod develops and commercializes Lenire, a bimodal neuromodulation medical device for treating tinnitus, supplying clinicians and…
BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
Novus DiagnosticsNovus Diagnostics builds a rapid point-of-care diagnostic platform using microfluidic electrochemical sensors and diagnostic algorithms for…
Phlox TherapeuticsPhlox Therapeutics develops precision RNA-based therapies to treat rare genetic cardiomyopathies, creating therapeutic candidates and…
Jazz PharmaceuticalsJazz Pharmaceuticals develops and commercializes medicines for people with rare diseases, focusing on therapies for epilepsies, cancers and…
Agomab TherapeuticsAgomab Therapeutics develops disease-modifying therapies for fibro-inflammatory conditions through TGFβ/ALK5 (TGFβR1) pathway targeting,…
ORCA TherapeuticsORCA Therapeutics develops oncolytic virus immunotherapies for prostate cancer, producing lead candidate ORCA-010 for treatment‑naive…